Avapritinib was also recently approved by the FDA, and the mPFS is 29.5 months in metastatic PDGFRA-D842V GIST patients [32], and 3.7 months in non-D842V GIST patients [33]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.